Thursday 29 May 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Pharma cos link up on Spanish psoriasis treatment

Pharma cos link up on Spanish psoriasis treatment

Pharmaceutical
26 March 2025

Spain-based drugmaker REIG JOFRE (BME: RJF) has signed a commercial agreement with LEO Pharma, a privately-held Danish firm specializing in medical dermatology and thrombosis. 

The partnership aims to strengthen the promotion of Enstilar (calcipotriol/betamethasone dipropionate foam), LEO’s innovative product for mild to moderate psoriasis within the scope of primary care in Spain. It is hoped that this work will help extend the treatment’s reach, improving patient access and enhancing support for healthcare professionals.

Enstilar’s unique formulation significantly improves anti-psoriatic response and has been recognized by Spanish trade group Farmaindustria as an incremental innovation, thanks to its advanced foam-based pharmaceutical formulation. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...

Pharmaceutical
Grifols posts positive Phase II/III trial of Flebogamma
17 March 2025
Pharmaceutical
LEO delivers double-digit growth ahead of 2026 IPO
26 February 2025
Pharmaceutical
DEBRA Research and LEO Pharma partner on EB
5 February 2025


Companies featured in this story

More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

IMUNON’s Stacy Lindborg on the long road to Phase III
Biotechnology
IMUNON’s Stacy Lindborg on the long road to Phase III
28 May 2025
Generics
Geropharm receives compulsory license for Novo Nordisk’s Ozempic
28 May 2025
Pharmaceutical
Pimicotinib demonstrates best-in-class potential in TGCT
28 May 2025
Biotechnology
InflaRx ditches vilobelimab Phase III trial in PG
28 May 2025
Biotechnology
FDA refuses to file Savara BLA for Molbreevi
28 May 2025
Pharmaceutical
GRIN raises $140 million and enters global pact for epilepsy candidate
28 May 2025
Biotechnology
CDC drops COVID-19 jab from routine vaccine schedules
28 May 2025

Company Spotlight

A biopharma company utilising small interfering RNAs (siRNAs) to improve and expand the reach of RNAi-based medicines.




More Features in Pharmaceutical

Pimicotinib demonstrates best-in-class potential in TGCT
28 May 2025
GRIN raises $140 million and enters global pact for epilepsy candidate
28 May 2025
Gilgamesh touts positive Phase IIa results for GM-2505 in MDD
28 May 2025
Lilly boosts pain pipeline with buy of SiteOne Therapeutics
28 May 2025


The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze